Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00177047 · ClinicalTrials.gov registry record · Phase 2
Autologous Transplant for Multiple Myeloma
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 363
- Enrollment target
NCT00177047: Completed Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
NCT00177047 is a Phase 2 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 363 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (173% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00177047, a Phase 2 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 363 participants
- Enrollment target
Study Summary
This is a study of a regimen of melphalan and autologous stem cells for patients with multiple myeloma. We hypothesize that this particular regimen will improve the survival of these patients.
Primary Outcome
Myeloma Response Definitions - Using International Uniform Response Criteria: Stringent Complete Response (sCR)requires, plus CR: * Normal free light chain ratio * Absence of clonal cells in bone marrow Complete Response (CR): * Absence of the original monoclonal paraprotein * \<5% plasma cells in a bone marrow aspirate and also on trephine bone biopsy * No increase in size or number of lytic bone lesions * Disappearance of soft tissue plasmacytomas.
Interventions
- DRUG Melphalan
- PROCEDURE Stem Cell Transplant
- DRUG Cyclophosphamide + Mesna
- BIOLOGICAL Granulocyte-colony stimulating factor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 363 participants |
| Start Date | 2004-04-20 |
| Est. Completion | 2020-08-01 |
| Phase | Phase 2 |
What the finished NCT00177047 record still lists
NCT00177047 is an interventional study that assigns participants to a tested intervention. The registered 363 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (173% higher).
The record links to 0 conditions, and to 4 interventions - of which Melphalan is the first listed.
NCT00177047 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00177047 about?
NCT00177047 is a clinical study titled "Autologous Transplant for Multiple Myeloma". This is a study of a regimen of melphalan and autologous stem cells for patients with multiple myeloma. We hypothesize that this particular regimen will improve the survival of these patients.
What is the current status of trial NCT00177047?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 363 participants. The study started on 2004-04-20. Estimated completion is 2020-08-01.
What interventions are being tested in trial NCT00177047?
The interventions under investigation include: Melphalan (DRUG), Stem Cell Transplant (PROCEDURE), Cyclophosphamide + Mesna (DRUG), Granulocyte-colony stimulating factor (BIOLOGICAL).
Who is sponsoring clinical trial NCT00177047?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00177047's enrollment target sits among peer trials
363 122nd of 2000 higher than 1,879 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06472245 · 363 participants · Phase 3
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- NCT04510597 · 364 participants · Phase 3
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
- NCT05098132 · 364 participants · Phase 1
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
- NCT05330221 · 364 participants · NA
Project 2: ACHIEVE- HF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI